华东医药：控股子公司DR10624注射液获美国FDA批准开展临床试验

Core Insights - The company announced that its subsidiary, Daor Bio, received FDA notification for the clinical trial application of DR10624 injection, which is approved for clinical trials in the U.S. for severe hypertriglyceridemia indications [1] - DR10624 is a globally innovative long-acting tri-specific agonist developed independently by Daor Bio, having previously completed Phase II clinical studies with positive topline results [1] - The uncertainty surrounding the drug's development is noted, but it is stated that this will not have a significant impact on the company's recent performance [1]